A Preliminary Study of Genetic Polymorphisms Potentially Related to the Adverse Effects of Aripiprazole | [Archives of Pharmacy Practice • 2023]

Author(s):

1. Katarzyna Guzek: Department of Genetics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University,Krakow,Poland

2. Adriana Stelmach: Department of Genetics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.

3. Alicja Rożnowska: Department of Genetics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.

4. Irena Najbar: Centre of Education, Research and Development, Babinski University Hospital, Krakow, Poland; Department of Psychiatry, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.

5. Łukasz Cichocki: Centre of Education, Research and Development, Babinski University Hospital, Krakow, Poland.

6. Anna Sadakierska- Chudy: Department of Genetics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University,Krakow,Poland

Abstract:

Aripiprazole is an atypical antipsychotic drug that is mainly transformed by the hepatic enzymes CYP2D6 and CYP3A4. Dose adjustment is recommended for CYP2D6-poor metabolizers. Aripiprazole is generally well tolerated by most adult patients, but occasionally adverse effects can occur in some individuals resulting in the drug being withdrawn. Recent studies suggested that other genes involved in drug metabolism, transport, and elimination can be related to the efficacy and safety of drug therapy. This study aimed to evaluate the differences in genetic variants between patients who tolerated the therapy well and those who experienced adverse effects leading to withdrawing the drug. The genetic profiling of 20 genes was performed using MassARRAY technology. No differences between both groups in the ABCB1, COMT, CYP2D6, CYP3A4, and CYP3A5 polymorphisms were found. Unexpectedly, we observed a higher frequency of homozygous CYP1A21F/*1F (78% vs. 45%) and CYP2B6*1/*1 (80% vs. 45%) as well as the frequency of CYP1A2 ultra-rapid metabolizes in the group with adverse effects. Moreover, a combined homozygous status (CYP1A2*1F/*1F/ CYP2B6*1/*1) has been exclusively identified in patients with adverse effects. To date, there are no findings about the possible role of CYP1A2 and CYP2B6 enzymes in aripiprazole metabolism. Thus, our preliminary data suggest that the CYP1A2*F and/or CYP2B6*1 alleles may contribute to the adverse effects of aripiprazole. Therefore, further studies on larger sample sizes are needed to confirm our findings.

Page(s): 13-18

DOI: 10.51847/bNMXd353X2

Published: Journal: Archives of Pharmacy Practice, Volume: 14, Issue: 2, Year: 2023

Keywords:

cytochrome P450 , phenotype , Aripiprazole , Adverse drug effect , Pharmacogenetics , SNP polymorphisms

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views